Smith J A, Bluestone J A
Ben May Institute for Cancer Research, Department of Pathology, University of Chicago, IL 60637, USA.
Curr Opin Immunol. 1997 Oct;9(5):648-54. doi: 10.1016/s0952-7915(97)80044-1.
Fc receptor nonbinding anti-CD3 monoclonal antibodies show promise for clinical application, in that they suppress graft rejection without the toxicity associated with conventional anti-CD3 antibody therapy. Recent studies suggest that the mechanism of soluble anti-CD3 antibody mediated immunosuppression involves partial signaling, induced cytokine deviation and Th1 cell inactivation.
不与Fc受体结合的抗CD3单克隆抗体在临床应用中显示出前景，因为它们能抑制移植排斥反应，且没有传统抗CD3抗体疗法相关的毒性。最近的研究表明，可溶性抗CD3抗体介导的免疫抑制机制涉及部分信号传导、诱导的细胞因子偏差和Th1细胞失活。
